全球生育补充剂市场：分析与预测（2022-2028 年）

在预测期内，全球生育补充剂市场规模预计将以约 7.8% 的复合年增长率增长。

全球不孕症患病率激增和肥胖率上升是推动市场增长的主要因素。 在预测期内，可支配收入的增加和久坐不动的生活方式也对市场产生了积极影响。

本报告研究全球生育补充剂市场，并提供有关市场收入、成分/产品/最终用户/分销商/地区的市场洞察、市场动态、公司概况等信息。

内容

第一章市场介绍

第 2 章调查方法和前提条件

• 孕期保健品市场调查流程
• 孕期保健品市场研究方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对生育补充剂市场的影响

第 6 章生育补充剂市场收入（十亿美元），2020-2028 年（预测）

第 7 章市场洞察：按成分分类

• 自然的
• 合成/天然和合成的混合物

第 8 章市场洞察：按产品分类

• 胶囊
• 药片
• 软胶囊
• 粉末
• 液体

第 9 章市场洞察：最终用户

• 男
• 女

第 10 章市场洞察：按分布

• 场外交易
• 处方

第 11 章市场洞察：按地区

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 其他地区

第 12 章生育补充剂市场：市场动态

• 市场驱动力
• 市场问题
• 影响分析

第 13 章生育补充剂市场：机遇

第 14 章生育补充剂市场：趋势

第15章需求侧与供给侧分析

• 需求方分析
• 供应方分析

第 16 章价值链分析

第 17 章衝突场景

• 竞争格局
  • 波特的五力分析

第十八章公司简介

• Fairhaven Health
• Coast Science
• LENUS Pharma GesmbH
• Orthomol
• Vitabiotics
• VH Nutrition LLC
• TTK HealthCare Ltd
• The Bird and Be Co. Inc.
• Bionova
• Exeltis USA, Inc.

第19章 免责事项

Global Fertility Supplement Market is expected to grow at a significant rate of around 7.8% during the forecast period. Fertility supplement contains nutrients, such as folic acid, fish oil, selenium, vitamin E, vitamin D, and others to enhance the fertility of the individuals. Surge in the prevalence of infertility globally and rising rates of obesity are the key drivers boosting the growth of the market. For instance, according to the World Health Organization, in 2021, there were around 48 million couples, and 186 million individuals suffering from infertility disease globally. Apart from this, an increase in disposable income and the high adoption of a sedentary lifestyle is also having a positive impact on the market during the forecast period.

Fairhaven Health; Coast Science; Lenus Pharma GesmbH; Bionova; Vitabiotics Ltd.; Orthomol; Exeltis USA, Inc.; The Bird and Be Co. Inc.; VH Nutrition LLC, and TTK HealthCare Ltd. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst product, tablet category to witness higher CAGR during the forecast period"

Based on product, the market is categorized into capsules, tablets, soft gels, powder, and liquids. The tablets segment is expected to grow with high CAGR rates during the forecast period. Excipients in high-quality supplements help in tablet absorption and disintegration. Although the natural coating enhances dissolution, several other factors including efficacy and quality influence absorption. These factors are expected to drive the growth of the market during the forecast period. Apart from this, the product's ease of absorption, cost-effectiveness, and disintegration are other factors propelling the growth of the market.

"Amongst end-user type, the female to hold a significant share in the market in 2020"

On the basis of end-user, the fertility supplement market is segmented into men and women. Women held the maximum share in the global market due to an increase in fertility issues among married infertile women. Moreover, companies are rapidly launching their product in the global market which is also driving the growth of the market during the forecast period. For instance, in May 2020, WellSource Nutraceuticals launched Methyl-NX to specifically address the unique design criteria to support in vitro fertilization and fertility programs. It was created to provide sufficient quantities of bioactive folate, essential B vitamins and omega-3.

"North America to hold a significant share in the market"

In 2020, North America held a significant share of the global fertility supplement market which is due to the rising population of infertile men and women. According to the data from the Centers for Disease Control and Prevention (CDC), in 2017, around 6 million women which are estimated to be around 10% of the US women population have difficulty in conceiving a child. Additionally, in the US, there were more than 15 out of every 100 adults aging 18 or more smoke, according to the CDC. Similarly, the healthcare expenditure of the U.S. is high which is another factor driving the market's growth.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Fertility Supplement Market
• 2.2. Research Methodology of the Fertility Supplement Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE FERTILITY SUPPLEMENT MARKET

6 FERTILITY SUPPLEMENT MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY INGREDIENT

• 7.1. Natural
• 7.2. Synthetic/ Blend of Natural & Synthetic

8 MARKET INSIGHTS BY PRODUCT

• 8.1. Capsules
• 8.2. Tablets
• 8.3. Soft Gels
• 8.4. Powder
• 8.5. Liquids

9 MARKET INSIGHTS BY END USER

• 9.1. Men
• 9.2. Women

10 MARKET INSIGHTS BY DISTRIBUTION

• 10.1. OTC
• 10.2. Prescribed

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 FERTILITY SUPPLEMENT MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 FERTILITY SUPPLEMENT MARKET OPPORTUNITIES

14 FERTILITY SUPPLEMENT MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Fairhaven Health
• 18.2. Coast Science
• 18.3. LENUS Pharma GesmbH
• 18.4. Orthomol
• 18.5. Vitabiotics
• 18.6. VH Nutrition LLC
• 18.7. TTK HealthCare Ltd
• 18.8. The Bird and Be Co. Inc.
• 18.9. Bionova
• 18.10. Exeltis USA, Inc.

19 DISCLAIMER